Clinical trial
The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
NCT06140576 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
- Lead sponsor
- Zhejiang Cancer Hospital
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- November 30, 2023
- Completion date
- December 31, 2026
- Enrollment
- 58 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.